PBAC Approves XIFAXAN(R) (Rifaxamin and#945;) 550 mg Cost Effectiveness in Australia

LONDON, May 24, 2013 -- (Healthcare Sales & Marketing Network) --Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrenc... Biopharmaceuticals, RegulatoryNorgine, Alfa Wassermann, XIFAXAN, TARGAXAN, hepatic encephalopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news